Detalhe da pesquisa
1.
B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
PLoS Pathog
; 16(2): e1008365, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32059024
2.
A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.
PLoS Pathog
; 14(7): e1007179, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30052684
3.
Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells.
J Virol
; 87(18): 10126-38, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23843639
4.
The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli.
J Virol
; 86(24): 13360-70, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23015717
5.
Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism.
Proc Natl Acad Sci U S A
; 107(7): 3146-51, 2010 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-20133771
6.
The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent manner.
J Virol
; 85(9): 4318-29, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21325409
7.
The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins.
J Virol
; 84(23): 12362-74, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20861254
8.
Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Oncotarget
; 8(27): 44266-44280, 2017 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28574826